• 1
    Lacroix M,Toillon RA,Leclercq G. Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004; 11: 497522.
  • 2
    Perou CM,Sorlie T,Eisen MB,van de RM,Jeffrey SS,Rees CA,Pollack JR,Ross DT,Johnsen H,Akslen LA,Fluge O,Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747752.
  • 3
    Carey LA,Perou CM,Livasy CA,Dressler LG,Cowan D,Conway K,Karaca G,Troester MA,Tse CK,Edmiston S,Deming SL,Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 24922502.
  • 4
    Althuis MD,Fergenbaum JH,Garcia-Closas M,Brinton LA,Madigan MP,Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 15581568.
  • 5
    Ma H,Bernstein L,Pike MC,Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006; 8: R43.
  • 6
    Garcia-Closas M,Brinton LA,Lissowska J,Chatterjee N,Peplonska B,Anderson WF,Szeszenia-Dabrowska N,Bardin-Mikolajczak A,Zatonski W,Blair A,Kalaylioglu Z,Rymkiewicz G, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006; 95: 1239.
  • 7
    McCabe A,Dolled-Filhart M,Camp RL,Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005; 97: 180815.
  • 8
    Camp RL,Chung GG,Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 13237.
  • 9
    Chatterjee N. A two-stage regression model for epidemiological studies with multivariate disease classification data. J Am Stat Assoc 2004; 99: 12738.
  • 10
    Kaptain S,Tan LK,Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10: 13952.
  • 11
    Fergenbaum JH,Garcia-Closas M,Hewitt SM,Lissowska J,Sakoda LC,Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 2004; 13: 66772.
  • 12
    DiVito KA,Charette LA,Rimm DL,Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004; 84: 10718.
  • 13
    Lal P,Tan LK,Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005; 123: 5416.
  • 14
    Saunders PT,Millar MR,Williams K,Macpherson S,Bayne C,O'Sullivan C,Anderson TJ,Groome NP,Miller WR. Expression of oestrogen receptor β (ERβ1) protein in human breast cancer biopsies. Br J Cancer 2002; 86: 2506.
  • 15
    Miyoshi Y,Akazawa K,Kamigaki S,Ueda S,Yanagisawa T,Inoue T,Yamamura J,Taguchi T,Tamaki Y,Noguchi S. Prognostic significance of intra-tumoral estradiol level in breast cancer patients. Cancer Lett 2004; 216: 11521.
  • 16
    Potischman N,Swanson CA,Siiteri P,Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88: 7568.
  • 17
    Calle EE,Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 57991.
  • 18
    Eliassen AH,Colditz GA,Rosner B,Willett WC,Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006; 296: 193201.
  • 19
    Fentiman IS,Hanby A,Allen DS,Key T,Meilahn EN. Hormone dependency of breast tumours developing in the Guernsey Cohort Study. Breast Cancer Res Treat 2006; 97: 2058.
  • 20
    Missmer SA,Eliassen AH,Barbieri RL,Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004; 96: 185665.
  • 21
    Howe LR,Chang SH,Tolle KC,Dillon R,Young LJ,Cardiff RD,Newman RA,Yang P,Thaler HT,Muller WJ,Hudis C,Brown AM, et al. HER-2/neu-induced mammary tumorigenesis and angiogenesis are reduced incyclooxygenase-2 knockout mice. Cancer Res 2005; 65: 101139.
  • 22
    Arpino G,Weiss H,Lee AV,Schiff R,De Placido S,Osborne CK,Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005; 97: 125461.
  • 23
    Gruvberger S,Ringner M,Chen Y,Panavally S,Saal LH,Borg A,Ferno M,Peterson C,Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001; 61: 597984.
  • 24
    Khan SA,Sachdeva A,Naim S,Meguid MM,Marx W,Simon H,Halverson JD,Numann PJ. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol Biomarkers Prev 1999; 8: 86772.
  • 25
    Shoker BS,Jarvis C,Clarke RB,Anderson E,Hewlett J,Davies MP,Sibson DR,Sloane JP. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999; 155: 181115.
  • 26
    Ness RB,Buhari A,Gutai J,Kuller LH. Reproductive history in relation to plasma hormone levels in healthy post-menopausal women. Maturitas 2000; 35: 14957.
  • 27
    Matthews J,Wihlen B,Tujague M,Wan J,Strom A,Gustafsson JA. Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 2006; 20: 53443.
  • 28
    Saji S,Hirose M,Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 2005; 56(Suppl 1): 216.
  • 29
    Allred DC,Brown P,Medina D. The origins of estrogen receptor α-positive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 2004; 6: 2405.